The potential epidemiological impact of a genital herpes vaccine for women

Sexually Transmitted Infections

Volumn 80, Issue 1, 2004, Pages 24-29

  Garnett, G P ^a   Dubin, G ^c   Slaoui, M ^b   Darcis, T ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; MALE; MATHEMATICAL MODEL; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; VACCINATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

CLINICAL TRIALS, PHASE III; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HUMANS; MODELS, BIOLOGICAL; RISK FACTORS; SEXUAL BEHAVIOR; SEXUAL PARTNERS; VACCINATION; VIRUS SHEDDING;

EID: 1242292255     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2002.003848     Document Type: Article

References (21)

1. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press, 1991.
2. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-61.
3. Langenberg AGM, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. N Engl J Med 1999;341:1432-8.
4. Wald A, Selke S, Warren T, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive patients. N Engl J Med 2000;342:844-50.
5. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999;131:14-20.
6. Corey L, Wald A. Genital herpes. In: Holmes K, et al, eds. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill, 1999:285-312.
7. Corey L, Langenberg AGM, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection. JAMA 1999;282:331-40.
8. Diamond C, Selke S, Ashley R, et al. Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. Sex Transm Dis 1998;26:221-5.
9. Anderson RM, Garnett GP. Mathematical models of the transmission and control of sexually transmitted diseases. Sex Transm Dis 2000;27:636-43.
10. Garnett GP, Røttingen JA. Measuring the risk of HIV transmission. AIDS 2001;15:641-3.
11. Laumann EO, Gagnon JH, Michael RT, et al. The social organization of sexuality: sexual practices in the United States. Chicago: Chicago University Press, 1994.
12. Garnett GP, Mertz KJ, Finelli L, et al. The transmission dynamics of gonorrhoea: modelling the reported behaviour of infected patients from Newark, New Jersey. Phil Trans R Soc Lond B Biol Sci 1999;354:787-97.
13. Blower SM, Boe C. Sex acts, sex partners, and sex budgets: implications for risk factor analysis and estimation of HIV transmission probabilities. J AIDS HR 1993;6:1347-452.
14. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
15. Halloren ME, Longini IM, Stuchiner CJ. Estimability and interpretation of vaccine efficacy using frailty mixing models. Am J Epidemiol 1996;144:83-97.
16. Stanberry LR, Jorgensen DM, Nahmias AJ. Herpes simplex viruses 1 and 2. In: Evans AS, Kaslow RA, eds. Viral infections of humans: epidemiology and control. 4th ed. New York: Plenum Medical, 1997:419-54.
17. Garnett GP. The influence of behavioural heterogeneity on the population level impact of potential prophylactic HIV-1 vaccines. J Roy Stat Soc Ser A 1998;161:209-25.
18. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from aymptomatic and asymptomatic source contacts. Sex Transm Dis 1985;12:33-9.
19. Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202.
20. Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997;99:1092-7.
21. White PJ, Garnett GP. Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2. Sex Transm Infect 1999;75:49-54.